CV Therapeutics Lets Innovex Do the Legwork--and Pay for Some of It, Too
Contract Sales Organizations have moved past their rent-a-rep past and are now trying to market themselves as full service marketing outsourcers which provide alternatives to co-marketing and outlicensing.. Innovex's recent deal with CV therapeutics, is a case-in-point and may provide a model for biotechs--and even some pharmaceutical companies--to follow in launching products on their own without incurring huge fixed costs.
You may also be interested in...
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.
Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.
The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.